Fusen Pharmaceutical Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Fusen Pharmaceutical.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 11.0% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
There's Reason For Concern Over Fusen Pharmaceutical Company Limited's (HKG:1652) Price
Dec 18
Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky
May 21Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27%
Mar 31Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky
Dec 14Here's Why Fusen Pharmaceutical (HKG:1652) Can Manage Its Debt Responsibly
Sep 02Fusen Pharmaceutical (HKG:1652) Seems To Use Debt Quite Sensibly
Apr 02A Look At Fusen Pharmaceutical's (HKG:1652) Share Price Returns
Mar 06We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide
Feb 08
Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals?
Jan 18Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?
Dec 28What You Need To Know About Fusen Pharmaceutical Company Limited's (HKG:1652) Investor Composition
Dec 07If You Had Bought Fusen Pharmaceutical (HKG:1652) Shares A Year Ago You'd Have Earned 34% Returns
Nov 20In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Fusen Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2024 | 425 | -90 | -127 | -33 | N/A |
| 3/31/2024 | 496 | -63 | -144 | -53 | N/A |
| 12/31/2023 | 566 | -36 | -162 | -73 | N/A |
| 9/30/2023 | 614 | -24 | -49 | 19 | N/A |
| 6/30/2023 | 663 | -11 | 64 | 110 | N/A |
| 3/31/2023 | 577 | -23 | 75 | 110 | N/A |
| 12/31/2022 | 492 | -35 | 87 | 110 | N/A |
| 9/30/2022 | 414 | -34 | -5 | 38 | N/A |
| 6/30/2022 | 337 | -34 | -96 | -34 | N/A |
| 3/31/2022 | 361 | -9 | -79 | 7 | N/A |
| 12/31/2021 | 386 | 17 | -62 | 48 | N/A |
| 9/30/2021 | 420 | 48 | -30 | 66 | N/A |
| 6/30/2021 | 454 | 79 | 3 | 83 | N/A |
| 3/31/2021 | 470 | 75 | 49 | 118 | N/A |
| 12/31/2020 | 487 | 70 | 95 | 153 | N/A |
| 9/30/2020 | 473 | 67 | 74 | 154 | N/A |
| 6/30/2020 | 458 | 65 | 53 | 154 | N/A |
| 3/31/2020 | 433 | 59 | 8 | 87 | N/A |
| 12/31/2019 | 407 | 53 | -37 | 20 | N/A |
| 9/30/2019 | 397 | 63 | -54 | 23 | N/A |
| 6/30/2019 | 387 | 72 | -71 | 26 | N/A |
| 3/31/2019 | 424 | 87 | -56 | 44 | N/A |
| 12/31/2018 | 462 | 102 | -42 | 63 | N/A |
| 9/30/2018 | 507 | 102 | 37 | 95 | N/A |
| 6/30/2018 | 493 | 98 | 68 | 82 | N/A |
| 3/31/2018 | 473 | 98 | N/A | 107 | N/A |
| 12/31/2017 | 453 | 97 | N/A | 133 | N/A |
| 9/30/2017 | 427 | 86 | N/A | 91 | N/A |
| 12/31/2016 | 442 | 95 | N/A | 172 | N/A |
| 12/31/2015 | 369 | 45 | N/A | 70 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 1652's forecast earnings growth is above the savings rate (2.3%).
Earnings vs Market: Insufficient data to determine if 1652's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if 1652's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 1652's revenue is forecast to grow faster than the Hong Kong market.
High Growth Revenue: Insufficient data to determine if 1652's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 1652's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 12:12 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fusen Pharmaceutical Company Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|